Lovastatin lowers the risk of breast cancer

a population-based study using logistic regression with a random effects model

Rimi Murakami, Chieh-Feng Chen, Shu-Yu Lyu, Ching En Lin, Pei Chuan Tzeng, Tzu Feng Wang, Juei Chin Chang, Ying-Hua Shieh, I. Fan Chen, Shihping Kevin Huang, Hui Wen Lin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Laboratory studies have demonstrated statin-induced apoptosis of cancer cells, including breast cancer cells, and evidence is accumulating on the mechanism of statin-induced apoptosis. However, despite numerous epidemiological studies, no consensus has been reached regarding the relationship between statin use and breast cancer risk. Methods: This retrospective case–control study enrolled 4332 breast cancer patients and 21,660 age-matched controls registered in the National Health Insurance program of Taiwan, which covers approximately 99% of the population. The study cases were women for whom a diagnosis of breast cancer (ICD-9-CM code 174.X) had been recorded in LHID2005 between January 1, 2004 and December 31, 2010. A logistic regression model was adjusted for potential confounding factors, including the level of urbanization, and the Charlson Comorbidity Index was applied to assess potential comorbidities. We also considered possible bias caused by random urbanization, because nutrition and lifestyle factors are related to breast cancer incidence. Results: Our results showed that lovastatin was associated with a lower risk of breast cancer (adjusted OR 0.596; 95% CI 0.497–0.714; p < 0.001), and atorvastatin exhibited a protective tendency against breast cancer (adjusted OR 0.887; 95% CI 0.776–1.013; p < 0.077). Conclusions: Although no consensus has been established regarding the relationship between statin use and breast cancer risk, our study indicated that lovastatin is a potential chemopreventive agent against breast cancer. Further detailed research is warranted.

Original languageEnglish
Article number1932
JournalSpringerPlus
Volume5
Issue number1
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Lovastatin
Logistic Models
Breast Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Population
Urbanization
National Health Programs
Comorbidity
Consensus
Apoptosis
International Classification of Diseases
Taiwan
Life Style
Epidemiologic Studies
Retrospective Studies

Keywords

  • Atorvastatin
  • Breast neoplasms
  • Fluvastatin
  • Lovastatin
  • Pravastatin
  • Simvastatin

ASJC Scopus subject areas

  • General

Cite this

Lovastatin lowers the risk of breast cancer : a population-based study using logistic regression with a random effects model. / Murakami, Rimi; Chen, Chieh-Feng; Lyu, Shu-Yu; Lin, Ching En; Tzeng, Pei Chuan; Wang, Tzu Feng; Chang, Juei Chin; Shieh, Ying-Hua; Chen, I. Fan; Huang, Shihping Kevin; Lin, Hui Wen.

In: SpringerPlus, Vol. 5, No. 1, 1932, 01.12.2016.

Research output: Contribution to journalArticle

Murakami, Rimi ; Chen, Chieh-Feng ; Lyu, Shu-Yu ; Lin, Ching En ; Tzeng, Pei Chuan ; Wang, Tzu Feng ; Chang, Juei Chin ; Shieh, Ying-Hua ; Chen, I. Fan ; Huang, Shihping Kevin ; Lin, Hui Wen. / Lovastatin lowers the risk of breast cancer : a population-based study using logistic regression with a random effects model. In: SpringerPlus. 2016 ; Vol. 5, No. 1.
@article{bb35817be6b648f789b881a8190b5334,
title = "Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model",
abstract = "Background: Laboratory studies have demonstrated statin-induced apoptosis of cancer cells, including breast cancer cells, and evidence is accumulating on the mechanism of statin-induced apoptosis. However, despite numerous epidemiological studies, no consensus has been reached regarding the relationship between statin use and breast cancer risk. Methods: This retrospective case–control study enrolled 4332 breast cancer patients and 21,660 age-matched controls registered in the National Health Insurance program of Taiwan, which covers approximately 99{\%} of the population. The study cases were women for whom a diagnosis of breast cancer (ICD-9-CM code 174.X) had been recorded in LHID2005 between January 1, 2004 and December 31, 2010. A logistic regression model was adjusted for potential confounding factors, including the level of urbanization, and the Charlson Comorbidity Index was applied to assess potential comorbidities. We also considered possible bias caused by random urbanization, because nutrition and lifestyle factors are related to breast cancer incidence. Results: Our results showed that lovastatin was associated with a lower risk of breast cancer (adjusted OR 0.596; 95{\%} CI 0.497–0.714; p < 0.001), and atorvastatin exhibited a protective tendency against breast cancer (adjusted OR 0.887; 95{\%} CI 0.776–1.013; p < 0.077). Conclusions: Although no consensus has been established regarding the relationship between statin use and breast cancer risk, our study indicated that lovastatin is a potential chemopreventive agent against breast cancer. Further detailed research is warranted.",
keywords = "Atorvastatin, Breast neoplasms, Fluvastatin, Lovastatin, Pravastatin, Simvastatin",
author = "Rimi Murakami and Chieh-Feng Chen and Shu-Yu Lyu and Lin, {Ching En} and Tzeng, {Pei Chuan} and Wang, {Tzu Feng} and Chang, {Juei Chin} and Ying-Hua Shieh and Chen, {I. Fan} and Huang, {Shihping Kevin} and Lin, {Hui Wen}",
year = "2016",
month = "12",
day = "1",
doi = "10.1186/s40064-016-3606-2",
language = "English",
volume = "5",
journal = "SpringerPlus",
issn = "2193-1801",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Lovastatin lowers the risk of breast cancer

T2 - a population-based study using logistic regression with a random effects model

AU - Murakami, Rimi

AU - Chen, Chieh-Feng

AU - Lyu, Shu-Yu

AU - Lin, Ching En

AU - Tzeng, Pei Chuan

AU - Wang, Tzu Feng

AU - Chang, Juei Chin

AU - Shieh, Ying-Hua

AU - Chen, I. Fan

AU - Huang, Shihping Kevin

AU - Lin, Hui Wen

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Laboratory studies have demonstrated statin-induced apoptosis of cancer cells, including breast cancer cells, and evidence is accumulating on the mechanism of statin-induced apoptosis. However, despite numerous epidemiological studies, no consensus has been reached regarding the relationship between statin use and breast cancer risk. Methods: This retrospective case–control study enrolled 4332 breast cancer patients and 21,660 age-matched controls registered in the National Health Insurance program of Taiwan, which covers approximately 99% of the population. The study cases were women for whom a diagnosis of breast cancer (ICD-9-CM code 174.X) had been recorded in LHID2005 between January 1, 2004 and December 31, 2010. A logistic regression model was adjusted for potential confounding factors, including the level of urbanization, and the Charlson Comorbidity Index was applied to assess potential comorbidities. We also considered possible bias caused by random urbanization, because nutrition and lifestyle factors are related to breast cancer incidence. Results: Our results showed that lovastatin was associated with a lower risk of breast cancer (adjusted OR 0.596; 95% CI 0.497–0.714; p < 0.001), and atorvastatin exhibited a protective tendency against breast cancer (adjusted OR 0.887; 95% CI 0.776–1.013; p < 0.077). Conclusions: Although no consensus has been established regarding the relationship between statin use and breast cancer risk, our study indicated that lovastatin is a potential chemopreventive agent against breast cancer. Further detailed research is warranted.

AB - Background: Laboratory studies have demonstrated statin-induced apoptosis of cancer cells, including breast cancer cells, and evidence is accumulating on the mechanism of statin-induced apoptosis. However, despite numerous epidemiological studies, no consensus has been reached regarding the relationship between statin use and breast cancer risk. Methods: This retrospective case–control study enrolled 4332 breast cancer patients and 21,660 age-matched controls registered in the National Health Insurance program of Taiwan, which covers approximately 99% of the population. The study cases were women for whom a diagnosis of breast cancer (ICD-9-CM code 174.X) had been recorded in LHID2005 between January 1, 2004 and December 31, 2010. A logistic regression model was adjusted for potential confounding factors, including the level of urbanization, and the Charlson Comorbidity Index was applied to assess potential comorbidities. We also considered possible bias caused by random urbanization, because nutrition and lifestyle factors are related to breast cancer incidence. Results: Our results showed that lovastatin was associated with a lower risk of breast cancer (adjusted OR 0.596; 95% CI 0.497–0.714; p < 0.001), and atorvastatin exhibited a protective tendency against breast cancer (adjusted OR 0.887; 95% CI 0.776–1.013; p < 0.077). Conclusions: Although no consensus has been established regarding the relationship between statin use and breast cancer risk, our study indicated that lovastatin is a potential chemopreventive agent against breast cancer. Further detailed research is warranted.

KW - Atorvastatin

KW - Breast neoplasms

KW - Fluvastatin

KW - Lovastatin

KW - Pravastatin

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=84994779303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994779303&partnerID=8YFLogxK

U2 - 10.1186/s40064-016-3606-2

DO - 10.1186/s40064-016-3606-2

M3 - Article

VL - 5

JO - SpringerPlus

JF - SpringerPlus

SN - 2193-1801

IS - 1

M1 - 1932

ER -